C87499 Activators
Pramel32, a member of the PRAME family, emerges as a protein with a predicted function in ubiquitin ligase-substrate adaptor activity, operating within the Cul2-RING ubiquitin ligase complex. This implies a crucial role in the regulation of protein degradation pathways. The ubiquitin-proteasome system is a central component of cellular homeostasis, responsible for selectively targeting proteins for degradation. In the context of Pramel32, its involvement in ubiquitin ligase-substrate adaptor activity suggests a role in facilitating the interaction between substrate proteins and the ubiquitin ligase complex, marking them for subsequent degradation. This function aligns with the broader cellular mechanisms aimed at maintaining protein quality control and regulating the levels of specific proteins in response to various cellular signals or conditions.
The orthologous relationships of Pramel32 with several human genes, including PRAMEF1, PRAMEF10, and PRAMEF11, hint at a degree of functional conservation across species. These orthologs likely share common regulatory mechanisms and functional pathways, contributing to the understanding of Pramel32's role in cellular processes. To unravel the mechanisms governing Pramel32's activation, it becomes crucial to explore the intricate web of signaling pathways and cellular processes that intersect with its predicted functions. A detailed examination reveals potential regulatory points at which chemicals may influence Pramel32 activation. For instance, inhibitors targeting components of the ubiquitin-proteasome system, such as NEDD8-activating enzyme (NAE) inhibitors like MLN4924 and Pevonedistat, may prevent ubiquitin-mediated degradation, thereby stabilizing Pramel32. Additionally, modulators of transcriptional processes, such as BET bromodomain inhibitors like JQ1, could indirectly impact Pramel32 expression by altering the chromatin landscape. The involvement of Pramel32 in specific pathways, like PI3K/AKT, Wnt/β-catenin, and NF-κB, suggests that chemicals influencing these pathways, such as PI3-kinase/mTOR dual inhibitors like PI-103 and GSK-3 inhibitors like SB216763, may indirectly regulate Pramel32 activity. These diverse regulatory mechanisms highlight the complexity of Pramel32 activation, suggesting a nuanced interplay between post-translational modifications, protein-protein interactions, and transcriptional regulation. In essence, Pramel32, with its predicted functions in ubiquitin ligase-substrate adaptor activity and association with critical cellular pathways, stands as a key player in cellular protein regulation, and understanding its activation involves navigating the intricate web of cellular signaling and degradation processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $280.00 | 1 | |
NEDD8-activating enzyme (NAE) inhibitor. Pramel32 is part of the Cul2-RING ubiquitin ligase complex. Inhibition of NAE by MLN4924 may disrupt ubiquitin ligase activity and potentially activate Pramel32 by preventing its ubiquitin-mediated degradation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor affecting protein degradation. Pramel32, being part of the Cul2-RING ubiquitin ligase complex, may be regulated by proteasomal degradation. Bortezomib inhibits proteasome activity, potentially leading to increased Pramel32 stability and activation. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
BET bromodomain inhibitor modulating gene expression. Pramel32, predicted to enable ubiquitin ligase-substrate adaptor activity, might be influenced by transcriptional regulation. JQ1 inhibits BET bromodomains, potentially altering the transcriptional landscape and indirectly affecting Pramel32 expression and function. | ||||||
Amlexanox | 68302-57-8 | sc-217630 | 10 mg | $160.00 | 2 | |
IKKε/TBK1 inhibitor modulating NF-κB signaling. Pramel32 activity might be influenced by NF-κB signaling. Amlexanox inhibits IKKε/TBK1, potentially affecting NF-κB activation and indirectly influencing Pramel32 function by modulating the signaling pathway it is associated with. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $260.00 $925.00 | 5 | |
p300/CBP HAT inhibitor affecting gene transcription. Pramel32 activity might be influenced by histone acetylation. C646 inhibits p300/CBP HAT, potentially altering the acetylation status of histones and indirectly affecting the transcriptional regulation of Pramel32 and its associated genes. | ||||||
(–)-Nutlin-3 | 675576-98-4 | sc-222086 sc-222086A | 1 mg 5 mg | $120.00 $215.00 | 2 | |
MDM2 inhibitor modulating p53 pathway. Pramel32 may be indirectly regulated by the p53 pathway. Nutlin-3 inhibits MDM2, potentially stabilizing p53 and indirectly influencing Pramel32 function through alterations in the cellular environment and p53-mediated gene expression. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $32.00 $128.00 | 3 | |
PI3-kinase/mTOR dual inhibitor affecting signaling pathways. Pramel32 may be associated with PI3K/AKT signaling. PI-103 inhibits PI3-kinase and mTOR, potentially impacting the PI3K/AKT pathway and indirectly influencing Pramel32 activity by modulating the upstream signaling cascade. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $70.00 $198.00 | 18 | |
GSK-3 inhibitor affecting Wnt/β-catenin signaling. Pramel32 orthologs are associated with Wnt signaling. SB216763 inhibits GSK-3, potentially affecting Wnt/β-catenin pathway and indirectly influencing Pramel32 activity by modulating the associated signaling cascade. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
HDAC inhibitor affecting histone acetylation. Pramel32 activity might be influenced by histone acetylation. Trichostatin A inhibits histone deacetylases (HDACs), potentially altering the acetylation status of histones and indirectly affecting the transcriptional regulation of Pramel32 and its associated genes. | ||||||
THZ1 | 1604810-83-4 | sc-507542 | 1 mg | $95.00 | ||
CDK7 inhibitor affecting transcription. Pramel32, predicted to enable ubiquitin ligase-substrate adaptor activity, may be influenced by transcriptional regulation. THZ1 inhibits CDK7, potentially affecting RNA polymerase II-mediated transcription and indirectly influencing Pramel32 expression and function. | ||||||